 BP is targeting at least $2 billion in cash cost savings by the end of 2026. Weaker margin in fuels and lower gas and oil prices impacted BP's results in the first quarter as well. Eli Lilly has agreed to buy biopharma company Morphic for $3.2 billion. In the deal, Lilly picks up experimental therapies for inflammatory bowel disease and other chronic illnesses. Morphic's stock is up 1% pre-market after soaring 75% yesterday.